Metastatic Colorectal Cancer Linked to Transcription Factors
|
By LabMedica International staff writers Posted on 03 Jan 2019 |

Image: Genome-wide human SNP array 6.0 GeneChip (Photo courtesy of Affymetrix).
Colorectal cancer (CRC) is a kind of malignant human tumor with high mortality around the world. The incidence of colorectal cancer shows a gender difference and is prone to the elderly.
The pathogenesis of colorectal cancer is complex, and some factors may increase the risk, such as inflammatory bowel disease, race, smoking history, dietary composition and so on. Until now, tumor metastasis remains the dominant lethal factor of colorectal cancer that cannot be effectively controlled.
A scientist at the Tsinghua University (Beijing, China) and his colleague used available RNA sequence, array-based genotype, DNA methylation, and mass spectrometry-based protein profile data to analyze samples from nearly 600 CRC patients with or without metastases. The two scientists considered patterns in liquid chromatography-mass spec-based proteomic data in 11 CRC patients with metastases and 79 without, from the Clinical Proteomics Tumor Analysis Consortium (CPTAC), along with RNA sequence data for 598 individuals with CRC who were assessed for the Cancer Genome Atlas (TCGA) project, including 88 individuals with metastases.
The duo obtained 589 unique masked copy number segment files and 371 unique DNA methylation datasets of COAD and READ patients from the NCI GDC data portal. When they compared transcript and protein expression profiles in tumor samples from metastatic and non-metastatic cases, they saw altered levels for eight transcription factors, particularly expression shifts that appeared to stem from copy number variation.
The team reported that transcript and protein expression of four transcription factors: HNF4A, HSF1, MECP2, and RAD21, appeared to shift in metastatic CRC, prompting subsequent bioinformatic, chromatin immunoprecipitation sequencing, and ATAC-seq analyses to narrow in on transcription factor targets and the long non-coding RNAs (lncRNAs) interacting with them. They also identified candidate biomarkers for metastases, as well as thousands of potential target genes for the transcription factors. The latter set was enriched for genes from pathways that include WNT signaling, RAS signal transduction, cell migration, and other processes previously implicated in the metastases of other tumor types.
The authors explained that in view of the high heterogeneity of colorectal cancer metastasis, it is urgent to identify molecular targets for clinical treatment. Their work comprehensively demonstrated the intrinsic functions of four transcription factors in colorectal cancer metastasis, which may extend our knowledge on the underlying mechanisms. The study was published on December 13, 2018, in the journal Scientific Reports.
Related Links:
Tsinghua University
The pathogenesis of colorectal cancer is complex, and some factors may increase the risk, such as inflammatory bowel disease, race, smoking history, dietary composition and so on. Until now, tumor metastasis remains the dominant lethal factor of colorectal cancer that cannot be effectively controlled.
A scientist at the Tsinghua University (Beijing, China) and his colleague used available RNA sequence, array-based genotype, DNA methylation, and mass spectrometry-based protein profile data to analyze samples from nearly 600 CRC patients with or without metastases. The two scientists considered patterns in liquid chromatography-mass spec-based proteomic data in 11 CRC patients with metastases and 79 without, from the Clinical Proteomics Tumor Analysis Consortium (CPTAC), along with RNA sequence data for 598 individuals with CRC who were assessed for the Cancer Genome Atlas (TCGA) project, including 88 individuals with metastases.
The duo obtained 589 unique masked copy number segment files and 371 unique DNA methylation datasets of COAD and READ patients from the NCI GDC data portal. When they compared transcript and protein expression profiles in tumor samples from metastatic and non-metastatic cases, they saw altered levels for eight transcription factors, particularly expression shifts that appeared to stem from copy number variation.
The team reported that transcript and protein expression of four transcription factors: HNF4A, HSF1, MECP2, and RAD21, appeared to shift in metastatic CRC, prompting subsequent bioinformatic, chromatin immunoprecipitation sequencing, and ATAC-seq analyses to narrow in on transcription factor targets and the long non-coding RNAs (lncRNAs) interacting with them. They also identified candidate biomarkers for metastases, as well as thousands of potential target genes for the transcription factors. The latter set was enriched for genes from pathways that include WNT signaling, RAS signal transduction, cell migration, and other processes previously implicated in the metastases of other tumor types.
The authors explained that in view of the high heterogeneity of colorectal cancer metastasis, it is urgent to identify molecular targets for clinical treatment. Their work comprehensively demonstrated the intrinsic functions of four transcription factors in colorectal cancer metastasis, which may extend our knowledge on the underlying mechanisms. The study was published on December 13, 2018, in the journal Scientific Reports.
Related Links:
Tsinghua University
Latest Pathology News
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
- New X-Ray Method Promises Advances in Histology
- Single-Cell Profiling Technique Could Guide Early Cancer Detection
- Intraoperative Tumor Histology to Improve Cancer Surgeries
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
- AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







